Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $23.34 is 53.86% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 24.12||$ 31|
|Low:||$ 22.08||$ 15.17|
Company Description (as filed with the SEC)
We are a latestage clinical biopharmaceutical company focused on the development and commercialization of novel, antibodybased therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including two pivotalstage product candidates--naxitamab and omburtamab--which target tumors that express GD2 and B7H3, respectively. We are developing naxitamab for the treatment of pediatric patients with relapsed or refractory, or R/R, highrisk neuroblastoma, or NB, and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, or CNS, leptomeningeal metastases, or LM, from NB. NB is a rare and almost exclusively pediatric cancer that develops in the sympathetic nervous system and CNS/LM is a rare and usually fatal complication of NB in which the disease spreads to the membranes, or meninges, surrounding the brain and spinal cord in the CNS. ... More ...
Nasdaq Official Price
Mar. 25, 2019
Mar. 25, 2019